| Coronavirus disease 2019 treatment: a review of early and emerging options EK McCreary, JM Pogue Open forum infectious diseases 7 (4), ofaa105, 2020 | 430 | 2020 |
| Effect of convalescent plasma on organ support–free days in critically ill patients with COVID-19: a randomized clinical trial H Abdelhady, M Abdelrazik, Z Abdi, D Abdo, A Abdulle, L Abel, ... Jama 326 (17), 1690-1702, 2021 | 189 | 2021 |
| Efficacy of Remdesivir in COVID-19 EK McCreary, DC Angus Jama 324 (11), 1041-1042, 2020 | 130 | 2020 |
| Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study JC Gallagher, MJ Satlin, A Elabor, N Saraiya, EK McCreary, E Molnar, ... Open forum infectious diseases 5 (11), ofy280, 2018 | 107 | 2018 |
| Open forum infectious diseases Infectious Diseases Society of America, HIV Medicine Association, ... Published by Oxford University Press on behalf of the Infectious Diseases …, 2014 | 105 | 2014 |
| Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections RK Shields, EK McCreary, RV Marini, EG Kline, CE Jones, B Hao, L Chen, ... Clinical Infectious Diseases 71 (3), 667-671, 2020 | 84 | 2020 |
| Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, A Kidwai, ... Jama 329 (1), 39-51, 2023 | 81 | 2023 |
| Healthcare practitioners’ views of social media as an educational resource AG Pizzuti, KH Patel, EK McCreary, E Heil, CM Bland, E Chinaeke, ... PLoS One 15 (2), e0228372, 2020 | 78 | 2020 |
| New perspectives on antimicrobial agents: cefiderocol EK McCreary, EL Heil, PD Tamma Antimicrobial agents and chemotherapy 65 (8), 10.1128/aac. 02171-20, 2021 | 76 | 2021 |
| Multicenter Cohort of Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA … EK McCreary, R Kullar, M Geriak, EJ Zasowski, K Rizvi, LT Schulz, ... Open Forum Infectious Diseases 7 (1), ofz538, 2020 | 68 | 2020 |
| Impact of bamlanivimab monoclonal antibody treatment on hospitalization and mortality among nonhospitalized adults with severe acute respiratory syndrome coronavirus 2 infection JR Bariola, EK McCreary, RJ Wadas, KE Kip, OC Marroquin, T Minnier, ... Open forum infectious diseases 8 (7), ofab254, 2021 | 66 | 2021 |
| Appropriateness of antibiotic prescribing in United States children’s hospitals: a national point prevalence survey AC Tribble, BR Lee, KB Flett, LK Handy, JS Gerber, AL Hersh, ... Clinical Infectious Diseases 71 (8), e226-e234, 2020 | 57 | 2020 |
| Isavuconazole is as effective as and better tolerated than voriconazole for antifungal prophylaxis in lung transplant recipients P Samanta, CJ Clancy, RV Marini, RM Rivosecchi, EK McCreary, ... Clinical Infectious Diseases 73 (3), 416-426, 2021 | 46 | 2021 |
| Effectiveness of casirivimab-imdevimab and sotrovimab during a SARS-CoV-2 Delta variant surge: a cohort study and randomized comparative effectiveness trial DT Huang, EK McCreary, JR Bariola, TE Minnier, RJ Wadas, JA Shovel, ... JAMA Network Open 5 (7), e2220957-e2220957, 2022 | 37 | 2022 |
| Interplay between rapid diagnostic tests and antimicrobial stewardship programs among patients with bloodstream and other severe infections M Beganovic, EK McCreary, MV Mahoney, B Dionne, DA Green, ... The Journal of Applied Laboratory Medicine 3 (4), 601-616, 2019 | 37 | 2019 |
| Association of subcutaneous or intravenous administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in adults with COVID-19 EK McCreary, JR Bariola, RJ Wadas, JA Shovel, MK Wisniewski, M Adam, ... JAMA Network Open 5 (4), e226920-e226920, 2022 | 31 | 2022 |
| Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support–free days in patients hospitalized with COVID-19: a randomized … S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, K Fareed, ... Jama 329 (14), 1183-1196, 2023 | 28 | 2023 |
| That escalated quickly: remdesivir's place in therapy for COVID-19 MR Davis, EK McCreary, JM Pogue Infectious diseases and therapy 9, 525-536, 2020 | 25 | 2020 |
| The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open … DT Huang, EK McCreary, JR Bariola, RJ Wadas, KE Kip, OC Marroquin, ... Trials 22 (1), 363, 2021 | 23 | 2021 |
| Vancomycin combined with clindamycin for the treatment of acute bacterial skin and skin-structure infections KA Wargo, EK McCreary, TM English Clinical Infectious Diseases 61 (7), 1148-1154, 2015 | 23 | 2015 |
